Kane Biotech (CVE:KNE) Sets New 52-Week Low – What’s Next?

Kane Biotech Inc. (CVE:KNE) hit a new 52-week low during mid-day trading on Wednesday . The company traded as low as C$0.03 and last traded at C$0.03, with a volume of 58176 shares traded. The stock had previously closed at C$0.04.

Kane Biotech Stock Performance

The company has a debt-to-equity ratio of -289.57, a current ratio of 0.90 and a quick ratio of 0.39. The stock has a market capitalization of C$5.02 million, a P/E ratio of -0.38 and a beta of 1.04. The company has a fifty day moving average of C$0.03 and a two-hundred day moving average of C$0.04.

Kane Biotech Company Profile

Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections. It offers revyve, an antimicrobial wound gel; and shampoos, shampoo bars, and scalp detoxifiers under the DermaKB brand.